KLK3 and familial pancreatic carcinoma: Along these lines, a direct comparison with commonly applied diagnostic tests when available, (CA19-9 and CEA levels for pancreatic cancer and PSA levels for prostate cancer), improved the discrimination of cancer patients, even though the difference was again not significant.